KR20140061559A - 글라티라머 아세테이트를 포함하는 약제 - Google Patents
글라티라머 아세테이트를 포함하는 약제 Download PDFInfo
- Publication number
- KR20140061559A KR20140061559A KR1020147012452A KR20147012452A KR20140061559A KR 20140061559 A KR20140061559 A KR 20140061559A KR 1020147012452 A KR1020147012452 A KR 1020147012452A KR 20147012452 A KR20147012452 A KR 20147012452A KR 20140061559 A KR20140061559 A KR 20140061559A
- Authority
- KR
- South Korea
- Prior art keywords
- patient
- medicament
- glatiramer acetate
- injection site
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims abstract description 55
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims abstract description 52
- 229960003776 glatiramer acetate Drugs 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 83
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 50
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 50
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 79
- 230000003902 lesion Effects 0.000 claims description 70
- 201000006417 multiple sclerosis Diseases 0.000 claims description 61
- 238000007920 subcutaneous administration Methods 0.000 claims description 44
- 238000002347 injection Methods 0.000 claims description 28
- 239000007924 injection Substances 0.000 claims description 28
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 26
- 230000001965 increasing effect Effects 0.000 claims description 24
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims description 18
- 210000004556 brain Anatomy 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 16
- 229940071643 prefilled syringe Drugs 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000003251 Pruritus Diseases 0.000 claims description 12
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 12
- 230000001186 cumulative effect Effects 0.000 claims description 12
- 206010022095 Injection Site reaction Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 208000024806 Brain atrophy Diseases 0.000 claims description 10
- 206010008479 Chest Pain Diseases 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000024780 Urticaria Diseases 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 230000007803 itching Effects 0.000 claims description 9
- 206010015150 Erythema Diseases 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 208000032843 Hemorrhage Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 230000009266 disease activity Effects 0.000 claims description 7
- 231100000321 erythema Toxicity 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 206010006784 Burning sensation Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 206010051290 Central nervous system lesion Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 206010042674 Swelling Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 206010037844 rash Diseases 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 4
- 208000000059 Dyspnea Diseases 0.000 claims description 4
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 208000010201 Exanthema Diseases 0.000 claims description 4
- 208000005577 Gastroenteritis Diseases 0.000 claims description 4
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 4
- 206010022078 Injection site inflammation Diseases 0.000 claims description 4
- 206010030124 Oedema peripheral Diseases 0.000 claims description 4
- 208000003435 Optic Neuritis Diseases 0.000 claims description 4
- 206010033557 Palpitations Diseases 0.000 claims description 4
- 206010067868 Skin mass Diseases 0.000 claims description 4
- 208000001871 Tachycardia Diseases 0.000 claims description 4
- 206010072731 White matter lesion Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 230000001269 cardiogenic effect Effects 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 208000032625 disorder of ear Diseases 0.000 claims description 4
- 201000005884 exanthem Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 230000035900 sweating Effects 0.000 claims description 4
- 230000006794 tachycardia Effects 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 206010008469 Chest discomfort Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 208000003164 Diplopia Diseases 0.000 claims description 3
- 206010014020 Ear pain Diseases 0.000 claims description 3
- 206010016059 Facial pain Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 206010067142 Immediate post-injection reaction Diseases 0.000 claims description 3
- 206010022067 Injection site haemorrhage Diseases 0.000 claims description 3
- 206010022081 Injection site mass Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010040030 Sensory loss Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 230000037007 arousal Effects 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 230000007844 axonal damage Effects 0.000 claims description 3
- 208000034158 bleeding Diseases 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 210000005013 brain tissue Anatomy 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 208000013465 muscle pain Diseases 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 230000001568 sexual effect Effects 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 206010010947 Coordination abnormal Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010016334 Feeling hot Diseases 0.000 claims description 2
- 206010060800 Hot flush Diseases 0.000 claims description 2
- 206010022086 Injection site pain Diseases 0.000 claims description 2
- 206010022107 Injection site urticaria Diseases 0.000 claims description 2
- 206010022998 Irritability Diseases 0.000 claims description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000011318 facial edema Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000028756 lack of coordination Diseases 0.000 claims description 2
- 208000018883 loss of balance Diseases 0.000 claims description 2
- 230000004461 rapid eye movement Effects 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 206010022061 Injection site erythema Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003007 myelin sheath Anatomy 0.000 claims 1
- 230000009711 regulatory function Effects 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 33
- 208000024891 symptom Diseases 0.000 description 24
- 238000012216 screening Methods 0.000 description 21
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 19
- 208000017547 Ectodermal dysplasia-syndactyly syndrome Diseases 0.000 description 15
- 238000001990 intravenous administration Methods 0.000 description 11
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022079 Injection site irritation Diseases 0.000 description 1
- 206010022093 Injection site pruritus Diseases 0.000 description 1
- 206010053425 Injection site swelling Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WCIDIJQCEUODDY-UHFFFAOYSA-N chloro(dimethyl)sulfanium Chemical compound C[S+](C)Cl WCIDIJQCEUODDY-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27468709P | 2009-08-20 | 2009-08-20 | |
| US61/274,687 | 2009-08-20 | ||
| US33761210P | 2010-02-11 | 2010-02-11 | |
| US61/337,612 | 2010-02-11 | ||
| PCT/US2010/002283 WO2011022063A1 (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127007115A Division KR20120090044A (ko) | 2009-08-20 | 2010-08-19 | 낮은 빈도의 글라티라머 아세테이트 치료법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167006001A Division KR20160038057A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140061559A true KR20140061559A (ko) | 2014-05-21 |
Family
ID=43605835
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147012452A Ceased KR20140061559A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
| KR1020177031069A Ceased KR20170123354A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
| KR1020127007115A Ceased KR20120090044A (ko) | 2009-08-20 | 2010-08-19 | 낮은 빈도의 글라티라머 아세테이트 치료법 |
| KR1020167006001A Ceased KR20160038057A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177031069A Ceased KR20170123354A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
| KR1020127007115A Ceased KR20120090044A (ko) | 2009-08-20 | 2010-08-19 | 낮은 빈도의 글라티라머 아세테이트 치료법 |
| KR1020167006001A Ceased KR20160038057A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
Country Status (34)
| Country | Link |
|---|---|
| US (15) | US8399413B2 (https=) |
| EP (5) | EP2405749B1 (https=) |
| JP (3) | JP6038653B2 (https=) |
| KR (4) | KR20140061559A (https=) |
| CN (3) | CN105770855A (https=) |
| AR (2) | AR077896A1 (https=) |
| AT (1) | AT15421U1 (https=) |
| AU (1) | AU2010284666B2 (https=) |
| BR (1) | BR112012003730A2 (https=) |
| CA (2) | CA2760802C (https=) |
| CY (2) | CY1114537T1 (https=) |
| CZ (2) | CZ29723U1 (https=) |
| DE (1) | DE202010018377U1 (https=) |
| DK (5) | DK2405749T3 (https=) |
| EA (3) | EA032287B1 (https=) |
| ES (4) | ES2689711T3 (https=) |
| HK (2) | HK1258008A1 (https=) |
| HR (4) | HRP20130677T1 (https=) |
| HU (2) | HUE031282T2 (https=) |
| IL (3) | IL218106A0 (https=) |
| LT (3) | LT2630962T (https=) |
| ME (2) | ME01536B (https=) |
| MX (1) | MX2012002082A (https=) |
| NZ (1) | NZ598661A (https=) |
| PL (4) | PL2405749T3 (https=) |
| PT (4) | PT2949335T (https=) |
| RS (2) | RS55607B1 (https=) |
| SG (2) | SG10201405806SA (https=) |
| SI (4) | SI2405749T1 (https=) |
| SK (1) | SK501352015U1 (https=) |
| SM (2) | SMT201700057T1 (https=) |
| TW (3) | TWI643614B (https=) |
| UA (1) | UA103699C2 (https=) |
| WO (1) | WO2011022063A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US8077333B2 (en) * | 2002-09-09 | 2011-12-13 | Canon Kabushiki Kaisha | Printing control apparatus and printing control method |
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| MX2015008754A (es) * | 2013-01-04 | 2016-04-11 | Teva Pharma | Caracterizacion de un medicamento relacionado con acetato de glatiramer. |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN103641897B (zh) * | 2013-11-27 | 2017-01-04 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
| CN104844697B (zh) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
| US9155775B1 (en) * | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| BR112022001138A2 (pt) | 2019-07-22 | 2022-03-15 | Actelion Pharmaceuticals Ltd | Métodos de tratamento de esclerose múltipla |
| KR102519053B1 (ko) | 2021-02-08 | 2023-04-06 | 건국대학교 산학협력단 | 염산가스의 농도 측정을 위한 수분 전처리 시스템 |
| KR102519054B1 (ko) | 2021-03-12 | 2023-04-06 | 건국대학교 산학협력단 | 나피온 드라이어와 수분 전처리장치의 결합시스템 |
| WO2023062511A1 (en) * | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| CA3220684A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| ES2017924B3 (es) | 1985-10-11 | 1991-03-16 | Duphar Int Res B V | Inyector automatico. |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| DK2239269T3 (da) | 1998-09-25 | 2013-04-29 | Yeda Res & Dev | Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| KR20110008112A (ko) | 1999-08-27 | 2011-01-25 | 제넨테크, 인크. | 항-ＥｒｂＢ2 항체 투여 치료 방법 |
| JP4328050B2 (ja) | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| IL150895A0 (en) | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| EP1294390B1 (en) | 2000-06-07 | 2006-01-04 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| WO2004043995A2 (en) | 2002-11-13 | 2004-05-27 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| AU2003275895B2 (en) | 2002-11-25 | 2009-02-05 | Tecpharma Licensing Ag | Auto-injector comprising a resettable releasing safety device |
| US7274347B2 (en) | 2003-06-27 | 2007-09-25 | Texas Instruments Incorporated | Prevention of charge accumulation in micromirror devices through bias inversion |
| RU2339397C2 (ru) | 2003-01-21 | 2008-11-27 | Йеда Рисерч Энд Дивелопмент Ко.Лтд. | Сор1 для лечения воспалительных заболеваний кишечника |
| US20070037740A1 (en) * | 2003-03-04 | 2007-02-15 | Irit Pinchasi | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| WO2004103297A2 (en) | 2003-05-14 | 2004-12-02 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| JP2007509981A (ja) | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
| HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
| EP1778286A4 (en) | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| AU2005226729B2 (en) * | 2004-03-25 | 2010-01-28 | Janssen Pharmaceutica N.V. | Imidazole compounds |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| JP5495490B2 (ja) | 2004-05-07 | 2014-05-21 | アレス トレーディング エスエイ | ランダム共重合体を用いる疾患の治療方法 |
| CN101039691B (zh) * | 2004-06-25 | 2013-07-31 | 魁北克益得生物医学公司 | 用于治疗神经疾病的组合物和方法 |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| ZA200702591B (en) | 2004-09-09 | 2009-03-25 | Teva Pharma | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| AR052321A1 (es) | 2004-10-29 | 2007-03-14 | Sandoz Ag | Procesos para la preparacion de un polipeptido |
| JP2008528589A (ja) | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
| WO2006089164A1 (en) | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2606194A1 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| MX2008016335A (es) | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Dispositivo automatico de inyeccion. |
| JP2009542864A (ja) | 2006-07-05 | 2009-12-03 | モメンタ ファーマシューティカルズ インコーポレイテッド | コポリマー１の調製のための改良法 |
| US20110123482A1 (en) * | 2007-10-01 | 2011-05-26 | The Johns Hopkins University | Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide |
| CA2702437C (en) | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| CA2697570C (en) | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| NZ598661A (en) * | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| MX2015008754A (es) | 2013-01-04 | 2016-04-11 | Teva Pharma | Caracterizacion de un medicamento relacionado con acetato de glatiramer. |
| US20140271630A1 (en) | 2013-03-12 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
-
2010
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 US US12/806,684 patent/US8399413B2/en not_active Expired - Fee Related
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 SM SM20170057T patent/SMT201700057T1/it unknown
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Ceased
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Ceased
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko not_active Ceased
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en not_active Revoked
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Ceased
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en not_active Ceased
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-19 RS RS20130293A patent/RS52885B/sr unknown
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
-
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
-
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
-
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/en unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
-
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
-
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-12-01 HK HK16113727.5A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
-
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
-
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20140061559A (ko) | 글라티라머 아세테이트를 포함하는 약제 | |
| AU2013203367B2 (en) | Low frequency glatiramer acetate therapy | |
| AU2016100455B4 (en) | Low frequency glatiramer acetate therapy | |
| AU2015101564B4 (en) | Low frequency glatiramer acetate therapy | |
| HK1234325B (en) | Dosing regimen for multiple sclerosis | |
| HK1234325A1 (en) | Dosing regimen for multiple sclerosis | |
| HK1188722A (en) | Low frequency glatiramer acetate therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20140508 Application number text: 1020127007115 Filing date: 20120319 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20141203 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20141203 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150330 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20151204 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150330 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| J201 | Request for trial against refusal decision | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20160304 Application number text: 1020127007115 Filing date: 20120319 |
|
| PJ0201 | Trial against decision of rejection |
Patent event date: 20160304 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20151204 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2016101001407 Request date: 20160304 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016101001407; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160304 Effective date: 20160714 Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160304 Effective date: 20160714 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20160714 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20160304 Decision date: 20160714 Appeal identifier: 2016101001407 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20160907 |
|
| WITB | Written withdrawal of application |